Hepatic inflammatory responses in liver fibrosis

Area of Science:

• Hepatology and immunology, focusing on liver disease pathogenesis.

Background:

• Chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and viral hepatitis, are marked by persistent inflammation and liver fibrosis.
• Liver fibrosis is a critical factor in long-term morbidity and mortality, leading to conditions like cirrhosis and liver cancer, particularly in NAFLD and nonalcoholic steatohepatitis (NASH).
• Inflammation involves complex interactions between various liver cells responding to injury and external signals, with single-cell technologies revealing immune cell heterogeneity and spatial distribution.

Purpose of the Study:

• To review the current understanding of inflammatory mediators and cells involved in liver disease.
• To explore the fibrogenic pathways driving liver fibrosis.
• To discuss the therapeutic implications and targets identified for liver inflammation and fibrosis.

Main Methods:

• Review of current scientific literature and advances in understanding liver disease pathogenesis.
• Focus on single-cell technologies to analyze immune cell heterogeneity and spatial organization in the liver.
• Analysis of inflammatory responses, hepatic stellate cell activation, and their role in fibrosis.

Main Results:

• Inflammatory responses involve diverse hepatic cell types, including macrophages, neutrophils, T cells, and innate lymphoid cells.
• Hepatic stellate cells (HSCs) are activated by inflammation and can modulate immune responses or become matrix-producing myofibroblasts.
• Advances have identified several potential therapeutic targets for liver inflammation and fibrosis, particularly in NAFLD/NASH.

Conclusions:

• Inflammation and fibrosis are central to chronic liver disease progression and outcomes.
• A detailed understanding of cellular and molecular mechanisms is crucial for therapeutic development.
• Targeting inflammatory pathways and fibrogenic processes offers promising strategies for treating liver diseases like NAFLD and NASH.